Archil Jaliashvili: The Real Battle Is Not About Blood Volume — It Is About Oxygen
Archil Jaliashvili, Co-Chief Executive Officer at GeoBio Pharm, Biotech Executive, Strategic Partner of BHOC and Precision Oxygen Therapeutics, shared BHOC – Biological Hemoglobin Oxygen Carrier’s post on LinkedIn:
”The problem is not staying – it is escalating.
Blood and plasma shortages are not just persisting; they are deepening by the day.
And now, new forces are piling on:
- new pandemics,
- wars and conflicts,
- natural disasters,
- logistical breakdowns,
- soaring costs,
- emerging viruses,
- and ever more demanding tests.
- cold chain problem
These are not isolated hurdles – they are a new reality that demands a new understanding.
What is that understanding?
It is this: we must rethink what blood truly is – what we are actually doing, and what we truly need.
Today we state this clearly:
We are not talking about a ‘blood substitute’.
That is the old language.
We are talking about an Precise Oxygenation Therapeutics – to support one of the many critical functions of blood.
BUT – as clear it is main , fundamental function for life, healing, functioning
And here is the key insight:
It is not only about whether blood is available or not.
Even when blood is present – even when supplies are adequate – the blood as an organ still needs support.
We must increase its oxygen-delivery capacity – not just in cases of massive blood loss , hemoglobin level or repeated transfusions, but as a proactive measure to meet the oxygen demands of every patient in crisis.
Because the real battle is not about volume – it is about oxygen.
And that changes everything.”
BHOC – Biological Hemoglobin Oxygen Carrier shared a post on LinkedIn:
”This BBC News article from April 11, 2001, reports that South Africa became the first country in the world to approve a human blood substitute for use in transfusions .
25 years ago, the world already recognized that oxygen delivery does not necessarily have to depend on donor blood.
Dr. Luc Noel was the Coordinator for Blood Transfusion Safety at the WHO in Geneva. He was quoted as saying, “If there is any alternative that is safer than the potential risks of transfusions, then it should be used”
Other posts featuring Archil Jaliashvili on Hemostasis Today.
-
Oct 10, 2026, 00:34Raphaëlle Dodart: Discussing the Mechanisms of Menstrual Hemostasis
-
Oct 10, 2026, 00:26Barbara Adams Krolak: Discussing the Growing Need for Blood Clot Prevention in Asia
-
Oct 9, 2026, 23:59Ana Pedrero Gil: Is Coagulopathy with Fibrinolysis Present in All Obstetric Hemorrhages?
-
Oct 9, 2026, 23:57Exploring the Psychosocial Needs of People with Bleeding Disorders in Kyrgyzstan – EAHAD
-
Oct 9, 2026, 23:53Bernard Slater Jr.: Serving on the Advisory Council for the NBDF West Virginia Chapter
-
Oct 9, 2026, 23:53Aurelio Maggio: Thalassemia Reports Real-Time Impact Factor Rises to 1.760
-
Oct 9, 2026, 23:52Stronger Connections, Stronger Organizations – World Federation of Hemophilia
-
Oct 9, 2026, 23:46Samuel Misiani Mbunya: Advancing Sickle Cell Care Through Collaboration at the 21st ASCAT Conference
-
Oct 9, 2026, 23:42Hadeel Swed: My First First-Author Publication in Thrombosis Research